Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NYSEAMERICAN:AZTR OTCMKTS:EMMA NASDAQ:ENVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.82-4.7%$0.51$0.17▼$2.93$2.61M-0.07161,471 shs1,896 shsAZTRAzitra$0.81+1.5%$1.18$0.70▼$4.44$2.82M-1.617.98 million shs112,364 shsEMMAEmmaus Life Sciences$0.01+1.8%$0.01$0.00▼$0.05$696K8.9938,954 shs793 shsENVBEnveric Biosciences$0.97-2.5%$1.19$0.85▼$8.33$3.15M0.58319,973 shs127,704 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-4.65%+11.56%+42.96%+293.85%-71.72%AZTRAzitra+1.50%-5.44%-20.26%-53.82%-78.23%EMMAEmmaus Life Sciences+1.83%-6.72%-28.39%-34.71%-51.74%ENVBEnveric Biosciences-2.51%+6.58%-12.62%-19.84%-86.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.82-4.7%$0.51$0.17▼$2.93$2.61M-0.07161,471 shs1,896 shsAZTRAzitra$0.81+1.5%$1.18$0.70▼$4.44$2.82M-1.617.98 million shs112,364 shsEMMAEmmaus Life Sciences$0.01+1.8%$0.01$0.00▼$0.05$696K8.9938,954 shs793 shsENVBEnveric Biosciences$0.97-2.5%$1.19$0.85▼$8.33$3.15M0.58319,973 shs127,704 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-4.65%+11.56%+42.96%+293.85%-71.72%AZTRAzitra+1.50%-5.44%-20.26%-53.82%-78.23%EMMAEmmaus Life Sciences+1.83%-6.72%-28.39%-34.71%-51.74%ENVBEnveric Biosciences-2.51%+6.58%-12.62%-19.84%-86.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AAZTRAzitra 0.00N/AN/AN/AEMMAEmmaus Life Sciences 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00931.03% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AAZTRAzitra$10K286.64N/AN/A$4.97 per share0.16EMMAEmmaus Life Sciences$16.65M0.04N/AN/A($0.88) per share-0.01ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.950.04∞N/AN/A-471.57%-296.50%11/12/2025 (Estimated)AZTRAzitra-$8.97MN/A0.00N/AN/AN/A-183.57%-138.65%11/11/2025 (Estimated)EMMAEmmaus Life Sciences-$6.45M-$0.10N/A∞N/A-24.20%N/A-14.00%N/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)Latest EMMA, ENVB, AZTR, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EMMAEmmaus Life SciencesN/A-$0.02N/A-$0.02N/A$2.82 million8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AAZTRAzitraN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70AZTRAzitraN/A1.241.24EMMAEmmaus Life SciencesN/A0.080.06ENVBEnveric BiosciencesN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%AZTRAzitra11.16%EMMAEmmaus Life Sciences7.42%ENVBEnveric Biosciences13.82%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%AZTRAzitra0.25%EMMAEmmaus Life Sciences35.00%ENVBEnveric Biosciences1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableAZTRAzitra103.53 million3.52 millionNot OptionableEMMAEmmaus Life Sciences6063.87 million41.51 millionNot OptionableENVBEnveric Biosciences203.25 million3.21 millionNot OptionableEMMA, ENVB, AZTR, and ATXI HeadlinesRecent News About These CompaniesEnveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 5, 2025 | finance.yahoo.comEnveric Biosciences Releases New Investor PresentationAugust 29, 2025 | tipranks.comEnveric Tanks on Successful TestsAugust 28, 2025 | baystreet.caEnveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric IndicationsAugust 28, 2025 | bakersfield.comBEnveric Biosciences Announces Preclinical Results Confirming Potential ...August 17, 2025 | businesswire.comEnveric Biosciences Reports Second Quarter 2025 Financial and Corporate ResultsAugust 15, 2025 | finance.yahoo.comEnveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesJuly 23, 2025 | finance.yahoo.comEnveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesJuly 23, 2025 | businesswire.comEnveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)July 15, 2025 | businesswire.comEnveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 - MorningstarJune 26, 2025 | morningstar.comMEnveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric DisordersJune 10, 2025 | businesswire.comEnveric Biosciences secures patent for sleep disorder moleculesJune 4, 2025 | investing.comEnveric Biosciences reports positive preclinical results for depression drug candidateMay 29, 2025 | gulfshorebusiness.comGEnveric Biosciences announces results from EB-003 trialMay 29, 2025 | finance.yahoo.comEnveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003May 28, 2025 | finance.yahoo.comEnveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative DiseaseMay 20, 2025 | finance.yahoo.comEnveric Biosciences Reports First Quarter 2025 Financial and Corporate ResultsMay 14, 2025 | businesswire.comEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024March 31, 2025 | bakersfield.comBEnveric Biosciences Participating in BIO-Europe Spring®March 17, 2025 | businesswire.comEnveric Biosciences to auction PsyAI trademark portfolioMarch 8, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMMA, ENVB, AZTR, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.82 -0.04 (-4.65%) As of 09/12/2025 03:44 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Azitra NYSEAMERICAN:AZTR$0.81 +0.01 (+1.50%) Closing price 09/12/2025 04:10 PM EasternExtended Trading$0.81 -0.01 (-0.62%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Emmaus Life Sciences OTCMKTS:EMMA$0.01 +0.00 (+1.83%) As of 09/12/2025 01:13 PM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Enveric Biosciences NASDAQ:ENVB$0.97 -0.03 (-2.51%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.99 +0.02 (+2.07%) As of 09/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
